My watch list
my.bionity.com  
Login  

7 Current news of phoremost

rss

You can refine your search further. Select from the filter options on the left to narrow down your results.

image description
The two startups NeoCura and PhoreMost announce research collaboration to explore novel cancer therapeutics

19-Jan-2022

NeoCura Bio-Medical Technology Co., Ltd., a RNA-based drug research and development company in China, and PhoreMost Limited, the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’, announced an oncology drug discovery research collaboration As part of the collaboration, ...

more

image description
PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Start-ups combine biotechnology and artificial intelligence

06-Jan-2022

PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech (POLARISqb), a NC-based quantum computing drug design company, announced a collaborationto study oncology targets currently considered ...

more

image description
PhoreMost closes £33M Series B financing

Start-up is advancing its pipeline of novel therapies for oncology and diseases of ageing

25-Mar-2021

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, announced it has completed an oversubscribed £33m ($46m) Series B investment round. The round was led by BGF, the UK’s most active growth economy investor, and included new investors ...

more

PhoreMost completes $15M Series-A round to enter drug discovery

Investment to fund expansion of operations and progression of drug target pipeline

22-May-2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has completed an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug ...

more

PhoreMost and Plexxikon collaborate to identify novel drug targets

16-Apr-2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo. Under the agreement, PhoreMost will apply its ...

more

PhoreMost Ltd and University of Cambridge collaborate

Identifying innovative drug targets for neurodegenerative disease

14-Oct-2016

PhoreMost Ltd (PhoreMost), a biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. The groups will study and translate essential cellular ...

more

PhoreMost Awarded £1.4M Innovate UK Funding to Develop Lead Oncology Programme

13-May-2015

PhoreMost Ltd announced that it has been selected to receive a funding award of £1.4M (approximately $2.14M USD) from the UK’s innovation agency, Innovate UK, to develop its lead oncology programme targeting mutant KRAS cancers.Based on PhoreMost’s proprietary Protein Interference technology, the ...

more

Page 1 From 1
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE